Replimune Group, Inc.

Equities

REPL

US76029N1063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
6.72 ^USD	-1.32%		-0.15%	-20.28%

May. 16	Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	CI
Apr. 08	Replimune Group Provides Interim Results for Skin Cancer Therapy	MT

Replimune Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022

November 03, 2022 at 08:13 am EDT

Replimune Group, Inc. reported earnings results for the second quarter and six months ended September 30, 2022. For the second quarter, the company reported net loss was USD 43.1 million compared to USD 29.36 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to USD 0.56 a year ago.
For the six months, net loss was USD 85.36 million compared to USD 56.67 million a year ago. Basic loss per share from continuing operations was USD 1.57 compared to USD 1.09 a year ago.

Latest news about Replimune Group, Inc.

Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	May. 16	CI
Replimune Group Provides Interim Results for Skin Cancer Therapy	Apr. 08	MT
Replimune Group, Inc. Announces Management Changes	Mar. 26	CI
Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024	Mar. 26	CI
Transcript : Replimune Group, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 10:45 AM	Mar. 14
Wedbush Raises Replimune Group's PT to $16 From $14 After Adjusting Financing Assumptions, Keeps Outperform Rating	Feb. 09	MT
Replimune Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Transcript : Replimune Group, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM	Jan. 08
Wedbush Cuts Replimune Group's PT to $14 From $52 After Narrow Complete Response Rate Miss in Phase 2 Trial of Skin Cancer Treatment Candidate; Keeps Outperform Rating	Dec. 06	MT
Barclays Lowers Price Target on Replimune Group to $13 From $50, Keeps Overweight Rating	Dec. 06	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Dec. 05	MT
Sector Update: Health Care	Dec. 05	MT
Replimune Group Shares Slide as Trial of Skin Cancer Treatment Candidate Failed to Meet Primary Endpoints	Dec. 05	MT
Transcript : Replimune Group, Inc. - Special Call	Dec. 05
Replimune's skin cancer drug fails in late-stage study	Dec. 05	RE
Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers	Dec. 05	CI
JPMorgan Adjusts Replimune Price Target to $38 From $42, Maintains Overweight Rating	Nov. 24	MT
Replimune Group Shares Fall After Fiscal Q2 Loss Widens; Company Sees Cash to Fund Operations Into H2 2025	Nov. 07	MT
Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer	Nov. 07	CI
Replimune Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 07	CI
Replimune Group Appoints Emily Hill as CFO	23-09-19	MT
Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer	23-09-19	CI
HC Wainwright Adjusts Price Target on Replimune Group to $50 From $51, Keeps Buy Rating	23-08-07	MT
Replimune Group, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-03	CI
Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors	23-07-20	CI

Chart Replimune Group, Inc.

Duration

Period

More charts

Company Profile

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The Company's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The Company's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-30 - American Society of Clinical Oncology Meeting - Abstract #9517

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.72 USD

Average target price

13.56 USD

Spread / Average Target

+101.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
REPLIMUNE GROUP, INC.	-20.28%	413M
MODERNA, INC.	+33.37%	50.85B
IQVIA HOLDINGS INC.	+1.55%	42.82B
LONZA GROUP AG	+49.96%	42.03B
CELLTRION, INC.	-4.22%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B
BIO-TECHNE CORPORATION	+7.36%	13.05B
MEDPACE HOLDINGS, INC.	+28.30%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.08B

Other Biotechnology & Medical Research